Progress Towards a Public Chemogenomic Set for Protein Kinases and a Call for Contributions
D. H. Drewry, C. I. Wells, D. M. Andrews, R. Angell, H. Al-Ali, A. D. Axtman, S. J. Capuzzi, J. M. Elkins, P. Ettmayer, M. Frederiksen, O. Gileadi, N. Gray, A. Hooper, S. Knapp, S. Laufer, U. Luecking, S. Muller, E. Muratov, R. A. Denny, K. S. Saikatendu, D. K. Treiber, W. J. Zuercher, T. M. Willson
Abstract
Protein kinases are highly tractable targets for drug discovery. However, the biological function and therapeutic potential of the majority of the 500+ human protein kinases remains unknown. We have developed physical and virtual collections of small molecule inhibitors, which we call chemogenomic sets, that are designed to inhibit the catalytic function of almost half the human protein kinases. In this manuscript we share our progress towards generation of a comprehensive kinase chemogenomic set (KCGS), release kinome profiling data of a large inhibitor set (Published Kinase Inhibitor Set 2 (PKIS2)), and outline a process through which the community can openly collaborate to create a KCGS that probes the full complement of human protein kinases.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The Kinase Chemogenomic Set (KCGS): An open science resource for kinase vulnerability identification
C. I. Wells, H. Al-Ali, … D. H. Drewry·bioRxiv·Dec 22, 2019
- Exploring the understudied human kinome for research and therapeutic opportunities
Nienke Moret, Changchang Liu, … Peter Karl Sorger·bioRxiv·Apr 2, 2020
- An optimal set of inhibitors for Reverse Engineering via Kinase Regularization.
Scott Rata, Jonathan Scott Gruver, … Leonid Peshkin·bioRxiv·Sep 26, 2020
- In depth analysis of kinase cross screening data to identify chemical starting points for inhibition of the Nek family of kinases
C. I. Wells, N. R. Kapadia, … D. H. Drewry·bioRxiv·May 14, 2017
- PKIS Deep Dive Yields a Chemical Starting Point for Dark Kinases and a Cell Active BRSK2 Inhibitor
T. Y. Tamir, D. H. Drewry, … A. D. Axtman·bioRxiv·Jun 15, 2020
- Predicting kinase inhibitors using bioactivity matrix derived informer sets
H. Zhang, S. S. Ericksen, … M. A. Newton·bioRxiv·Jan 28, 2019